MEDICAL FEE DISPUTE RESOLUTION FINDINGS AND DECISION

GENERAL INFORMATION

Requestor Name Respondent Name

Memorial Compounding Pharmacy Christus Health

MFDR Tracking Number Carrier's Austin Representative

M4-17-3252-01 Box Number 17

MFDR Date Received

July 7, 2017

REQUESTOR'S POSITION SUMMARY

Requestor's Position Summary: "Memorial Compounding has not received any correspondence with explanation

of review or benefits."

Amount in Dispute: \$602.67

RESPONDENT'S POSITION SUMMARY

Respondent's Position Summary: "Payment has been made disputed as the medications were not

preauthorized."

Response Submitted by: Broadspire

SUMMARY OF FINDINGS

Dates of Service	Disputed Services	Amount In Dispute	Amount Due
January 16, 2017	Pharmacy Services – Compound	\$602.67	\$602.67

FINDINGS AND DECISION

This medical fee dispute is decided pursuant to Texas Labor Code §413.031 and applicable rules of the Texas Department of Insurance, Division of Workers' Compensation.

Background

- 1. 28 Texas Administrative Code §133.307 sets out the procedures for resolving medical fee disputes.
- 2. 28 Texas Administrative Code §134.502 sets out the procedures for pharmaceutical benefits.
- 3. 28 Texas Administrative Code §134.503 sets out the fee guidelines for pharmaceutical services.
- 4. 28 Texas Administrative Code §134.530 sets out the closed formulary requirements for claims not subject to certified networks.
- 5. The insurance carrier reduced payment for the disputed services with the following claim adjustment codes:
 - 39 Denied Medication Not Authorized

<u>Issues</u>

- 1. Is Christus Health's reason for denial of payment supported?
- 2. Is Memorial Compounding Pharmacy (Memorial) entitled to reimbursement for the compound in question?

Findings

1. Memorial is seeking reimbursement of \$602.67 for a compound dispensed on January 16, 2017. Christus Health denied the disputed compound with claim adjustment reason code 39 – "Denied – Medication Not Authorized."

28 Texas Administrative Code §134.530(b)(2) states that preauthorization is only required for:

- drugs identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp
 (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates;
- any compound that contains a drug identified with a status of "N" in the current edition of the ODG
 Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and
 any updates; and
- any investigational or experimental drug for which there is early, developing scientific or clinical evidence demonstrating the potential efficacy of the treatment, but which is not yet broadly accepted as the prevailing standard of care as defined in Labor Code §413.014(a).

The division finds that the compound in question does not include a drug identified with a status of "N" in the current edition of the ODG, *Appendix A*. Broadspire, acting on behalf of Christus Health, failed to articulate any arguments to support the denial for preauthorization. Therefore, the division concludes that the compound in question did not require preauthorization and Christus Health's denial of payment for this reason is not supported. Therefore, the compound in dispute will be reviewed for reimbursement.

- 2. 28 Texas Administrative Code §134.503 applies to the compounds in dispute and states, in pertinent part:
 - (c) The insurance carrier shall reimburse the health care provider or pharmacy processing agent for prescription drugs the lesser of:
 - (1) the fee established by the following formulas based on the average wholesale price (AWP) as reported by a nationally recognized pharmaceutical price guide or other publication of pharmaceutical pricing data in effect on the day the prescription drug is dispensed:
 - (A) Generic drugs: ((AWP per unit) x (number of units) x 1.25) + \$4.00 dispensing fee per prescription = reimbursement amount;
 - (B) Brand name drugs: ((AWP per unit) x (number of units) $\times 1.09$) + \$4.00 dispensing fee per prescription = reimbursement amount;
 - (C) When compounding, a single compounding fee of \$15 per prescription shall be added to the calculated total for either paragraph (1)(A) or (B) of this subsection; or
 - (2) notwithstanding §133.20(e)(1) of this title (relating to Medical Bill Submission by Health Care Provider), the amount billed to the insurance carrier by the:
 - (A) health care provider; or
 - (B) pharmacy processing agent only if the health care provider has not previously billed the insurance carrier for the prescription drug and the pharmacy processing agent is billing on behalf of the health care provider.

The compound in dispute was billed by listing each drug included in the compound and calculating the charge for each drug separately as required by 28 Texas Administrative Code §134.502(d)(2).

Each ingredient is listed below with its corresponding reimbursement amount as applicable.

Ingredient	NDC &	Price/	Total	AWP Formula	Billed Amt	Lesser of
	Туре	Unit	Units	§134.503(c)(1)	§134.503	(c)(1) and
					(c)(2)	(c)(2)
Compound Fee	NA	\$15.00	1	\$15.00	\$15.00	\$15.00
Versapro Cream	38779252903	\$3.20	43.68	\$3.20 x 43.68 x	\$109.20	\$109.20
	Brand Name	33.20	gm	1.09 = \$152.36		
Amitriptyline	38779018904	\$18.24	2.4	\$18.24 x 2.4 x	\$42.17	\$42.17
HCI	Generic	\$10.24	gm	1.25 = \$54.72	\$42.17	\$42.17
Gabapentin USP	38779246109	\$59.85	3.0	\$59.85 x 3 x 1.25	\$156.75	\$156.75
	Generic		gm	= \$224.44		
Ethoxy Diglycol	38779190301	\$0.342	3.6	\$0.342 x 3.6 x	\$1.23	\$1.23
	Generic	ŞU.342	ml	1.25 = \$1.54		
Bupivacaine HCl	38779052405	\$45.60	1.2	\$45.60 x 1.2 x	\$48.02	\$48.02
	Generic		gm	1.25 = \$68.40		
Flurbiprofen	38779036209	\$36.58	4.8	\$36.58 x 4.8 x	\$168.72	\$168.72
	Generic		gm	1.25 = \$219.48		
Amantadine HCl	38779041105	\$24.225	4.8	\$24.225 x 4.8 x	\$61.58	\$61.58
	Generic	<i>γ</i> 24.225	gm	1.25 = \$145.35		
					Total	\$602.67

The total reimbursement is therefore \$602.67. This amount is recommended.

Conclusion

For the reasons stated above, the Division finds that the requestor has established that additional reimbursement is due. As a result, the amount ordered is \$602.67.

ORDER

Based on the submitted information, pursuant to Texas Labor Code Section 413.031 and 413.019 (if applicable), the division has determined the requestor is entitled to additional reimbursement for the disputed services. The division hereby ORDERS the respondent to remit to the requestor \$602.67, plus applicable accrued interest per 28 Texas Administrative Code §134.130, due within 30 days of receipt of this order.

Authorized Signature

	Laurie Garnes	September 1, 2017
Signature	Medical Fee Dispute Resolution Officer	Date

YOUR RIGHT TO APPEAL

Either party to this medical fee dispute has a right to seek review of this decision in accordance with Rule §133.307, effective May 31, 2012, 37 Texas Register 3833, applicable to disputes filed on or after June 1, 2012.

A party seeking review must submit a **Request to Schedule a Benefit Review Conference to Appeal a Medical Fee Dispute Decision** (form **DWC045M**) in accordance with the instructions on the form. The request must be received by the division within **twenty** days of your receipt of this decision. The request may be faxed, mailed or personally delivered to the division using the contact information listed on the form or to the field office handling the claim.

The party seeking review of the MFDR decision shall deliver a copy of the request to all other parties involved in the dispute at the same time the request is filed. **Please include a copy of the** *Medical Fee Dispute Resolution Findings* **and** *Decision* together with any other required information specified in 28 Texas Administrative Code §141.1(d).

Si prefiere hablar con una persona en español acerca de ésta correspondencia, favor de llamar a 512-804-4812.